Blue Marble Biomaterials Announces Intent to Offer Equity Shares to the Public

First biomaterials company to utilize Regulation A+

MISSOULA, Mont.--()--Blue Marble Biomaterials (Blue Marble) today announced its intent to offer equity shares to the public through Regulation A+, a type of equity crowdfunding regulated by the Securities and Exchange Commission. A natural biochemical pioneer, Blue Marble intends to use the capital raised through its online public offering to expand production capabilities and research and develop new natural chemicals.

Blue Marble Biomaterials produces naturally derived, drop-in replacement ingredients (biochemicals) that replace synthetic, petroleum-based chemicals (petrochemicals)—which can be found in 95% of consumer products used every day.

“When people realize that they are feeding their children products with ingredients manufactured from petroleum and ending their day by rubbing crude-oil derived products on their face, they are horrified,” said Colby Underwood, co-CEO of Blue Marble. “Consumers are increasingly concerned about the environment and what they are putting into and onto their bodies and those of their families, and those concerns are driving a demand for change. We’re giving manufacturers a way to meet that demand.”

Blue Marble is partnering with Manhattan Street Capital (MSC) to host the company’s “Test the Waters” campaign and additional activities. MSC specializes in providing businesses with the services and information to raise growth capital through a Regulation A+ offering.

The “Test the Waters” process offers businesses the opportunity to gauge investor interest before committing to the expenses involved in a Regulation A+ offering. Regulation A+ offerings must be qualified by the Securities and Exchange Commission before any sales of shares may be made.

Regulation A+ differs from other popular crowdfunding methods, such as Kickstarter, in that investors buy equity shares in the company.

“We’ve seen companies have great success with Regulation A+ and we’re both excited by the future that this capital will make possible and proud to be able to offer equity shares in our company to people that can get behind us and help make a change,” said Underwood.

Visit the Blue Marble Regulation A+ page here: www.manhattanstreetcapital.com/blue-marble-biomaterials.

About Blue Marble Biomaterials

Blue Marble Biomaterials is a subsidiary of Blue Marble Energy Corporation. Blue Marble Biomaterials manufactures renewable specialty chemicals for the food, fragrance, cosmetics, and personal care industries in a zero-waste, carbon neutral production facility in Missoula, Montana. Its mission is to replace petroleum-based chemicals with fully sustainable, zero carbon specialty chemicals. For more information on Blue Marble go to: www.bluemarblebio.com.

NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED AND, IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT FILED BY THE COMPANY WITH THE SEC HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND.

Contacts

Blue Marble Biomaterials
Joanne Matsusaka
joanne.matsusaka@bluemarblebio.com

Release Summary

Blue Marble Biomaterials today announced its intent to offer equity shares to the public through Regulation A+, a type of equity crowdfunding regulated by the Securities and Exchange Commission.

Contacts

Blue Marble Biomaterials
Joanne Matsusaka
joanne.matsusaka@bluemarblebio.com